451 citations,
March 2005 in “Endocrine Reviews” The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.
7 citations,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
23 citations,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
2 citations,
May 2012 in “Annals of Oncology” Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.
68 citations,
April 2014 in “Journal of Molecular Endocrinology” The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
1 citations,
July 2011 in “Climacteric” Long-term estrogen therapy in postmenopausal women can improve certain health markers, hair loss is common regardless of hormone use, stopping estrogen doesn't increase breast cancer risk, smoking does, and a balanced BMI is linked to lower mortality.
56 citations,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
May 2024 in “Journal of clinical medicine” Spironolactone is safe for treating female hair loss, but the safety of other drugs is uncertain.
55 citations,
April 2010 in “Cancer and Metastasis Reviews” TGFβ's manipulation of inflammation and immune cells affects cancer spread, suggesting new treatment strategies and biomarkers.
April 2024 in “Academic dermatology” Dermatologists should carefully manage hair loss in cancer patients to improve their quality of life.
431 citations,
October 2008 in “Current Medicinal Chemistry” Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.
403 citations,
December 2018 in “Cell stem cell” Understanding phenotypic plasticity is crucial for developing effective cancer therapies.
21 citations,
March 2019 in “Critical Reviews in Clinical Laboratory Sciences” The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
7 citations,
September 2023 in “Cancer Treatment Reviews” Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.
October 2010 in “International Journal of Dermatology” An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.
March 2010 in “Ejc Supplements” ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
June 2023 in “Journal of multidisciplinary sciences (Online)” PCOS is linked to a higher risk of endometrial cancer but not ovarian or breast cancer, and more research is needed on its role in cancer development and treatment effects.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
1 citations,
September 2020 in “Endocrinology, Diabetes & Metabolism Case Reports” The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.
2 citations,
October 2021 in “Exploration of targeted anti-tumor therapy” Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.
4 citations,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
20 citations,
July 2006 in “Veterinary dermatology” Melatonin helped some Pomeranian dogs regrow hair, but it wasn't linked to estrogen receptors.
2 citations,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
38 citations,
June 2015 in “Expert Opinion on Therapeutic Targets” Blocking the prolactin receptor might help treat various diseases, but more research is needed.
13 citations,
August 1980 in “Cancer” Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.
34 citations,
November 2017 in “Gynecological Endocrinology” A transwoman developed a brain tumor after nine years of hormone therapy, suggesting a possible link between the treatment and tumor development.
May 1993 in “Drugs & Therapy Perspectives” Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
25 citations,
June 2019 in “Endocrine Related Cancer” Mutations in certain receptors can cause diseases and offer new treatment options.
12 citations,
December 2012 in “Current Drug Targets” The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.
6 citations,
January 2010 in “Neoplasma” Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.